Glioblastoma (GBM) remains the most lethal malignant tumours. Gboxin, an oxidative
phosphorylation inhibitor, specifically restrains GBM growth by inhibiting the activity of F0F1 …

Cancer-specific inhibitors that reflect the unique metabolic needs of cancer cells are rare.
Here we describe Gboxin, a small molecule that specifically inhibits the growth of primary …

Subcellular organelles play critical roles in cell survival. In this work, a novel photodynamic
therapy (PDT) drug delivery and phototoxicity on/off nano-system based on graphene oxide …

The tumor microenvironment (TME), comprising cancer cells and stroma, plays a significant
role in determining clinical outcomes, which makes targeting cancer cells in the TME an …

Mitochondria‐mediated apoptosis (MMA) is a preferential option for cancer therapy due to
the presence of cell‐suicide factors in mitochondria, however, low permeability of …

Glioma features high fatality rate and short survival time of patients due to its fast growth
speed and high invasiveness, hence timely treatment of early‐stage glioma is extremely …

Glioblastoma (GB) is the more frequent and malignant brain tumour. In spite of all efforts, the
median overall survival of GB patients remains approximately 15 months under therapy. The …

Minimal therapeutic advances have been achieved over the past two decades for
glioblastoma (GBM), which remains an unmet clinical need. Here, hypothesis‐driven stimuli …

Glioblastoma (GBM) is an intractable malignancy with high recurrence and mortality.
Combinatorial therapy based on temozolomide (TMZ) and cisplatin (CDDP) shows …

Glioblastoma multiforme (GBM) is a fatal central nervous system tumor without effective
treatment. Chemotherapeutic agents are mainstays in the treatment of glioblastoma …